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 Abstract 
Objectives: Dry powder formulations are extensively used to improve the stability of antibodies. 
Spray drying is one of important methods for protein drying. This study investigated the effects of 
trehalose, hydroxypropyl beta cyclodextrin (HPBCD) and beta cyclodextrin (BCD) on the stability 
and particle properties of spray dried IgG.  
Methods: D-optimal design was employed for experimental design as well as analysis and 
optimization of the variables. The size and aerodynamic behavior of particles were determined using 
laser light scattering and glass twin impinger, respectively. In addition, stability, ratio of beta sheets, 
and morphology of antibody were analyzed using size exclusion chromatography, IR spectroscopy, 
and electron microscopy, respectively. 
Results: Particle properties and antibody stability were significantly improved in the presence of 
HPBCD. In addition, particle aerodynamic behavior, in terms of fine particle fraction (FPF), 
enhanced up to 52.23%. Furthermore, antibody was better preserved not only during spray drying, 
but also during long term storage. In contrast, application of BCD resulted in the formation of larger 
particles. Although trehalose caused inappropriate aerodynamic property, it efficiently decreased 
antibody aggregation.  
Conclusion: HPBCD is an efficient excipient for development of inhalable protein formulations. In 
this regard, optimal particle property and antibody stability was obtained with proper combination of 
cyclodextrins and simple sugars, such as trehalose. 
Keywords: Antibody, Spray dry, D-optimal, Trehalose, Hydroxypropyl beta cyclodextrin, Beta cyclodextrin  
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 Introduction 
Monoclonal antibodies (mAbs) as a fast growing category of biopharmaceuticals, play an 
emerging role in the management of cancer and autoimmune disorders (1). More than 30 mAbs 
have already been approved for clinical use. Moreover, a broad range of therapeutic antibodies are 
also undergoing clinical trials (2). The majority of these formulations are administered 
parenterally. However, recent findings suggest pulmonary route as a potential alternative for local 
and/or systemic delivery of proteins/peptides (3). There are several obstacles in the formulation of 
inhalable proteins or peptides including intrinsic instability (4). Furthermore, efficient pulmonary 
delivery requires highly concentrated stable antibody in every dose (5). In this regard, aggregation 
and surface adsorption is commonly reported in concentrated liquid formulations (6). Therefore, 
dry powder formulation is suggested to enhance the stability of the product (7-8). 
Spray drying is one of the promising methods in particle engineering and can produce 
particulate systems with size ranges between 1-5 µm suitable for inhalation (9). This method has 
also been frequently used for the development of peptide and protein formulations. In this process, 
the atomized protein solution is dried by introduction to pre-heated air. Exposure to heat is the 
limiting step in spray drying, because extended heating can cause degradation of the proteins (10). 
Therefore, a suitable design of formulation is critical to minimize thermal and mechanical stresses 
during processing. 
Various excipients, such as polyols (mannitol, trehalose, sucrose) (8, 11-14) and amino acids (15-
16) are utilized to improve protein stability and particle properties. In this regard, cyclodextrins, as 
a novel class of excipients, are used to improve thermal stability, permeability and solubility. In 
addition, they are reported to prevent protein aggregation in various formulations (17-19). In 
particular, cyclodextrins more effectively improved stability in comparison to trehalose (20). 
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 Moreover, combination of the two excipients produced synergistic effects in the stability of freeze 
dried proteins (21). In this regard, statistical experimental design is implemented to obtain the 
appropriate ratio of different excipients.   
Statistical experimental design is a very useful technique to evaluate the effect of independent 
variables on a specific response with minimizing the number of experiments. Specifically, 
simultaneous change in parameters can be analysed by modelling of the data with multiple 
regression method. This helps optimize the variables to obtain the best results (22-23). In particular, 
D-optimal method is an effective tool to study the qualitative and quantitative variables together with 
high efficacy. It has been shown that this method is suitable for the optimization of formulation and 
spray drying variables (22, 24). 
This study evaluated the effects of different excipients, particularly cyclodextrins, on the 
particle properties, as well as antibody stability and characterized the optimum formulation by 
means of D-optimal method. 
2. Materials and methods 
2.1. Materials  
Hydroxypropyl beta cyclodextrin (HPBCD) was obtained from Acros (Belgium), and beta 
cyclodextrin (BCD) was obtained from Sigma (USA). Trehalose dihydrate, potassium phosphate 
dibasic and disodium sulfate were purchased from Merck (Germany). Human IgG (with molecular 
weight of about 150 kDa) was purchased from Kedrion (Italy). Prior to each investigation, low 
molecular weight additive of antibody solution was removed by dialysis (cut off: 15 kDa).  
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 2.2. Spray drying 
Solutions of antibody were prepared by dissolving appropriate amounts of IgG, HPBCD, BCD and 
trehalose which were indicated in D-optimal method in deionized water with final solid 
concentrations of about 1 mg/mL. Spray drying was performed using a lab scale Buchi-191 spray 
dryer (Buchi, Switzerland) with inlet temperature of 100 ºC, air flow rate of 700 L/h, liquid feed rate 
of 1.7 mL/min, and aspiration rate of 100%. 
2.3. Laser light scattering  
Laser light scattering (Malvern Instruments, UK) was applied to determine particle size. 
Approximately, 10 mg of each sample was suspended in 5 mL of acetonitrile and sonicated for 2 min 
(Starsonic, Italy). Particle size was then measured in obscurations between 0.15 and 0.20, and 
particle size distribution was defined by (d90%−d10%)/d50% as span parameter. 
2.4. Scanning electron microscopy (SEM) 
The morphology of spray dried particles was evaluated by scanning electron microscopy  
(XL30, the Netherland). Briefly, all samples were coated with a gold layer at 25ºC, and subjected to 
scanning at accelerated voltage of 250 kV. 
2.5. Size exclusion chromatography 
The percentage of soluble IgG aggregations, as a critical indicator for stability (25), was determined 
by size exclusion chromatography (SEC). Briefly, a 300 mm TSK 3000 SWXL column (Tosoh 
Biosep, Germany) was used to separate monomers from aggregated antibody. The mobile phase was 
consisted of 0.1 M disodium hydrogen phosphate and 0.1 M sodium sulfate (pH=6.8). A Waters 
pump (USA) was employed to supply an isocratic mobile phase with flow rate of 0.5 mL/min, 
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 injection volume of 20 µL and protein concentration of 2.5 mg/mL. Finally, protein concentrations 
were determined by a UV detector (Waters, USA) at 280 nm. All experiments were performed in 
triplicate. 
2.6. Fourier transformation infrared spectroscopy (FT-IR) 
Samples were prepared by mixing 2 mg of spray dried formulations and 200 mg KBr. The mixture 
was then compressed to produce a clear tablet. Infrared spectrums were then recorded by a Nicolet 
Magna spectrometer, and Jasco Spectra Manager
®
 software was used to evaluate the changes in 
secondary structure. In particular, second derivative spectrum of amide I region (1600–1700 cm−1) 
was used to find the peak position of deconvoluted spectra. Finally, the percentage of beta sheets, 
alpha helixes and turns was calculated by mixed Gaussian/Lorentzian function considering their 
absorption in 1640 cm
−1 
and 1695-1690 cm
−1
, 1660 – 1650 cm−1, and 1690-1665 cm−1, respectively 
(26). 
2.7. In Vitro Drug Deposition 
Aerodynamic behavior of spray dried formulations was assessed using a twin stage impinge (TSI; 
Copley, UK) as apparatus A in European Pharmacopoeia. Briefly, HPMC capsules (size 3) were 
filled with 15 mg of spray dried formulations, placed in Cyclohaler, and attached to the throat of 
TSI.  Aerodynamic properties of powders were then tested in the air flow rate of 60 L/min for 5 sec. 
Each section of TSI was washed with water and antibody content was subsequently determined 
using Bradford assay.  
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 2.8. Experimental design 
Design expert
® 
(trial version, 8.0.0) was applied to design the D-optimal model for the evaluation of 
the effects of excipients on responses, and to find the optimal formulation. The ratios of BCD, 
HPBCD and trehalose to antibody (0 to 1 and center point of 0.5) were selected as independent 
variables. Process yield, fine particle fraction (FPF), particle size and span, antibody stability in 
terms of aggregation and beta sheet content were evaluated as experimental responses. The data 
were fitted to an appropriate model by multiple regression and the best model was selected for each 
response based on ANOVA (P-value<0.05) and lack of fit with P-value<0.05. The optimum results 
were selected based on the curvature of response surface plots. 
3. Results  
3.1. D-optimal model 
Aqueous solutions containing antibody and excipients were spray dried in 18 runs. As mentioned in 
materials and methods, several combinations of BCD, HPBCD, trehalose and antibody was 
formulated. Afterwards, yield, fine particle fraction (FPF), particle size distribution, stability and 
antibody secondary structure were determined for each formulation (Table 1). Subsequently, the 
effect of each independent variable as well as their interaction on each response was determined 
(Table 2).  
3.2. Yield 
Process yields were calculated as the amount of collected powder divided by the total solid content 
of feed solution (range: 15.60 to 45.16%). Overall, the fitted model on the spray drying yield was 
determined by 26.98 + 1.38 A + 2.18 B + 7.51C + 1.04 AB + 2.72 AC; where A, B, and C define 
trehalose, HPBCD, and BCD, respectively. This indicates that yield is best fitted to a modified two 
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 factor interaction (2FI) model (Table 2, P<0.0001). In fact, particles containing BCD or HPBCD 
produced higher yields. In contrast, the total yield did not seem to be dependent on the concentration 
of trehalose when it was used as the sole excipient. However, co-formulation of trehalose with BCD 
led to a significant increase in the yield. In this regard, Figure 1 demonstrates the interaction between 
BCD and trehalose in which maximum yield was harvested with the highest ratio of these excipients. 
3.3. Particle size and shape 
Particles produced in all formulations demonstrated unimodal and narrow size distribution in range 
of 1.20 to 5.34µm. According to SEM picture (Fig.2) formulations containing one excipient (BCD, 
HPBCD, or trehalose) at the ratio of 1:1 to antibody exhibited as donut-shape after spray drying. In 
addition, particles containing only HPBCD showed deeper concave surface, and those containing all 
excipients (optimum formulation) demonstrated more spherical shape with some wrinkles on the 
surface. 
Overall, particle size was determined by the model of; 3.16 - 0.71A - 0.23B + 0.67C - 0.57A
2
 - 
0.98B
2
 + 0.99C
2
 + 0.59AB; where A, B, and C define trehalose, HPBCD, and BCD, respectively. 
This indicates that particle size is best fitted to a modified quadratic model (P<0.0001, Table 2). In 
particular, there were a positive correlation between the ratio of BCD and the particle size (β: +0.67, 
P<0.0001). On the other hand, trehalose negatively influenced particle size (β:-0.71, P<0.0001). 
Moreover, the interaction between the ratio of trehalose and HPBCD (AB) showed that the largest 
particles were obtained in the curvature point with medium ratios of these components (Fig. 3). 
The span parameter (size distribution) varied from 0.55 to 2.26. Overall, size distribution was 
determined by 1.25 - 0.39A + 0.015B + 0.18C - 0.38 A
2
 - 0.29B
2
 + 0.66C
2
 + 0.21AB + 0.13AC - 
0.12BC; where A, B, and C define trehalose, HPBCD, and BCD, respectively. This indicates that a 
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 modified quadratic model is best fitted to span data (Table 2; P: 0.004).  Furthermore, there were an 
inverse relationship between the ratio of trehalose (β: -0.015) and size distribution. Whereas, 
increases in the levels of HPBCD (β: 0.05) or BCD (β: 0.8) significantly expanded the span 
parameter. Interestingly, there was a linear relationship between particle size and span (Fig.4). 
Furthermore, the effect of interaction between trehalose and HPBCD on span was similar to their 
effect on size (Fig. 5). Therefore, the narrowest size distribution was obtained when either HPBCD 
or trehalose was applied in maximum ratios. 
3.4. Aerodynamic properties 
In vitro deposition studies revealed that aerodynamic properties of particles were considerably 
affected by formulation content. Indeed, fine particle fraction (FPF) as an index of particle 
aerodynamic behavior varied from 7.86 to 52.23%. Overall, FPF fitted model was determined by 
16.49 - 5.58A+ 7.03B + 0.33C - 5.34A
2
 + 10.35B
2
 + 4.80C
2
 - 6.41 AB - 2.61AC - 4.15BC; where A, 
B, and C define trehalose, HPBCD, and BCD, respectively. This implies that a quadratic model is 
the best fitted model to the FPF data (Table 2, P: 0.0004). In particular, FPF depended mainly on 
trehalose (β: -5.58, P: 0.001)  and HPBCD ratios (β: 7.03, P: 0.0004). In other words, FPF enhanced 
with increase of HPBCD ratio but decreased with trehalose. In the meantime, BCD produced no 
significant effect on FPF. 
Figure 6 shows the response surface plot for the effects of HPBCD and trehalose as well as the 
interaction of HPBCD with BCD. The results of this experiment indicated that more inhalable 
particles, higher FPF, were obtained when HPBCD was used in the highest level (Fig. 6A). 
Moreover, BCD content negatively influenced FPF when co-formulated with HPBCD (Fig. 6B).  
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 3.5. Stability 
The stability test was designed based on the guidance of FDA for biological products. The thermal 
stability tests included intermediate and long-term storage at 30°C or accelerated condition at 40°C. 
The test sought to be conducted every 3 months or at shorter intervals for accelerate test (27). 
Antibody stability in terms of aggregation was evaluated immediately after processing and in 
accelerated conditions (70% humidity at 40°C). Formulation of antibody without any excipients was 
susceptible to aggregation during spray drying as well as when stored at 40°C. In contrast, all 
applied excipients, especially trehalose and HPBCD, inhibited aggregation with different strengths. 
Overall, monomer content immediately after spray drying was determined by  96.81+ 1.25A + 1.81B 
+ 0.98C - 1.47 AB; where A, B, and C define trehalose, HPBCD, and BCD, respectively. This 
indicates a modified 2FI model for the protective effects of various excipients (Table 2), in which 
HPBCD and trehalose effectively inhibited aggregation (Fig. 7). Analyzing the adjusted model 
immediately after spray drying revealed that HPBCD was more effective than trehalose in the  
inhibition of aggregation during spray drying (coefficient of trehalose: 1.25 Vs. HPBCD: 1.81). 
These results were comparable to the long-term stability model. In particular, monomer content after 
30 days storage at 40ºC was determined by 94.63 + 1.92A + 2.36B + 1.72C - 2.07 AB - 0.63AC - 
0.64BC. Likewise, this value after 90 days was determined by the following model: 90.58 + 3.43A + 
3.69B + 2.98C - 2.08A B - 2.43AC - 1.56 BC. Table 2 indicates the protective effects of all 
excipients against aggregation. In addition, the protective effect of trehalose became more evident 
during long-term storage. 
Secondary structure of protein demonstrates the folding pattern as well as stability in various 
conditions. In the second derivative of FTIR spectra (Fig. 8), the main band in amide I region (1640 
and 1695 cm
-1
) is related to beta sheet content. As presented in Table 1, beta sheet content in various 
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 formulations varied between 41.1 to 66.74%. Indeed, spray drying of pure protein caused major 
transformations in this band (Fig. 8). Whereas, the intensity of 1640 cm
-1
 band in formulations 
containing trehalose was higher than those containing no excipient or those containing HPBCD or 
BCD. In fact, the fitted model on beta sheet content was determined by 60.59 + 6.11 A + 1.94 B - 
8.09 A
2 + 4.35 B
2 - 3.57 AB; where A, B, and C define trehalose, HPBCD, and BCD, respectively. 
This indicates a modified quadratic model and higher beta sheet content in samples containing 
trehalose. HPBCD also preserved beta sheet content (β: 1.94), though less effectively compared to 
trehalose (β: 6.11). Surprisingly, combination of two protective agents (trehalose and HPBCD) 
caused a significant decrease (β: -3.75) in the beta sheet content (Fig. 9; P: 0.0005). 
 
Discussion 
In this study we evaluated the effects of trehalose, HPBCD and BCD on particle properties as 
well as stability of spray dried IgG formulations.  
The harvesting yield is normally between 30-40% in protein dry powder preparation using 
bench top spray dryer (28). It mainly depends on the special cyclone design of the spry drying 
apparatus (28). The results of this study, however, indicates that cyclodextrins as the formulation 
variable can also influence the yield. As depicted in Fig. 1, increasing the ratio of BCD in 
formulations containing trehalose enhanced particle separation and caused entrapment in receiver.  
This might be due to an increase in particle size. In fact, formulations containing BCD had larger 
particle size. Hence, it is more likely for large particles to precipitate in reservoir and, thereby, 
increase the yield.   
JU
ST
 AC
CE
PT
ED
 Larger particles were obtained with BCD. In contrast, formulations containing HPBCD or trehalose 
produced smaller particles (Table 2). In this regard, droplet size and drying pattern are two 
determinant factors of particle size (29-30). In particular, Peclet number is a valuable factor to 
estimate the particle size, shape and surface morphology. It is calculated as: Pei = k/8Di; where k is 
the evaporation rate, and Di is diffusion coefficient of solute in aqueous medium of droplets during 
spray drying (30). Components with lower aqueous solubility demonstrate larger Peclet number (30). 
In this study, particle size was positively correlated with the ratio of BCD, while it was inversely 
related to the ratio of HPBCD and trehalose. This is explained by lower aqueous solubility of BCD 
(31) compared with HPBCD and trehalose. Thereby, BCD results in larger Peclet number and finally 
increases particle size. Likewise, the inverse relationship between the ratio of HPBCD and trehalose 
with particle size can be due to higher aqueous solubility of HPBCD and trehalose (32) and 
consequently lower Peclet number. Furthermore, trehalose tends to accumulate in particle core 
during spray drying and reduces particle size (33-35).  
Surface tension is another determinant of particle size (29). Although BCD does not influence 
surface tension, HPBCD decreases water surface tension, resulting in lower droplet interfacial 
tension  (36). In this regard, interfacial tension is inversely related with particle size because of 
easier detachment of droplets when surface tension is reduced (37), and consequent particles will be 
smaller. Therefore, small particle size with HPBCD can be attributed to both reduced pecklet 
number and surface tension. In contrast, although higher ratio of trehalose in aqueous formulation 
increases the surface tension (38), we observed  that co-formulation of trehalose with antibody 
produced particles with small size (Table 2). 
Trehalose decreased particle size (Table 2) and FPF (Fig. 6).On the other hand, HPBCD decreased 
the particle size but enhanced the FPF. In this regard, BCD increased particle size, but did not 
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 significantly influenced particle aerodynamic behaviour. This implies that particle size is not the sole 
determinant of FPF. In fact, it is determined by both partcile size and cohesive interaction forces 
between the partciles (39). In this regard, trehalose increases inter molecuar attraction (40) and 
causes sticky agglomarates(4).This might explaine infavorable effects of trehalose on FPF inspite of 
size reduction. HPBCD dcreased partcile size and cohesive interaction forces. Thereby, it efficiently 
improved aerodynamic behaviour of the particles. Cyclodextrins have been successfully used in 
many studies as FPF enhancer. For instance, Li et al demonestrated that formulations containing 
dimethyl beta cyclodextrin exhibited superior powder dispersibility compared to those containing 
trehalose or lactose (41). Similarly, salbutamol dry powder formulation with dimethyl beta 
cyclodextrin showed higher FPF in comparison to formulations containing lactose (42). Moreover, 
budesonide formulation with cyclodextrins enhanced particle respirable fraction up to 67% (43). 
Although BCD decreases cohesive interaction between the particles, it increased particle size (Table 
2).This might be the reason behind the inefficiency of BCD to improve FPF (P: 0.786). Taken 
together, HPBCD with desirable effects on both particle size and cohesive interaction forces 
produced particles suitable for inhalation. 
Antibodies are more stable in dry powder formulations than are in solutions. This is achieved by 
various mechanisms including glass dynamics or water substitution in solid matrix (11, 44). Recent 
studies showed that polyols improve glass dynamics and are capable of substituting water molecules 
(44-45). Hence, several polyols have been used for the preservation of peptides and proteins in spray 
drying (12). We found that trehalose, HPBCD and BCD decreased protein aggregation during spray 
drying and/or in long term storage. In contrast, the formulation without any excipients was 
dramatically susceptible to aggregation. In particular, HPBCD preserved antibody more efficiently 
during spray drying than did the other two excipients. This is explained by the fact that HPBCD is a 
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 hydrophilic cyclodextrin with surface active properties. In fact, aggregation mainly occurs in the 
water interface because of production of numerous droplets with large surface area during spraying 
(46). In addition, hydrophilic cyclodextrins can also prevent thermal-induced unfolding of proteins 
(47). Furthermore, cyclodextrins are cyclic oligosaccharides with lipophilic properties in the interior 
cavity (48). Thereby, they inhibit aggregation via covering the aromatic residues which are 
suggested to be the most important part of aggregation nucleus (49). Previous investigations have 
also showed that beta cyclodextrines (with 7-membered sugar ring molecule) are more effective than 
alpha (with 6-membered sugar ring molecule) or gama derivatives (with 8-membered sugar ring 
molecule). This is because of better docking of aromatic amino acids in the interior cavity of BCD 
(49). In addition, Tavornvipas et al, showed that branched beta cyclodextrins more effectively inhibit 
lysozyme aggregation. In this way, our results showed that HPBCD as hydrophilic branched 
cyclodextrin provided superior inhibitory effect against antibody aggregation than does BCD. 
Although HPBCD decreased protein aggregation more effectively during spray drying, trehalose 
provided better protection of antibody in long term. This indicates that formation of glassy state 
during long term storage is more important. Thereby, excipients with positive effect on protein 
surface inhibit protein-protein adherence via modification of hydrogen bonds and glassy state (50-
51). 
FTIR spectroscopy is a well-known method to obtain general information about proteins secondary 
structure (52-54). The native structure of antibody in aqueous solutions contains about 60% beta- 
sheet. FTIR spectroscopy of antibody solution have demonstrated dramatic changes at temperatures 
over 90°C (52). Hence, spray drying at 100°C is expected to cause significant perturbations and 
unfolding in the structure. In addition to high temperature, water evaporation and solidification can 
also induce structural alteration. The results showed an efficient water replacement property for 
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 trehalose (Table 2, β: 6.11). This implies that it can easily form hydrogen bounds with protein 
surface. HPBCD also replaces water and produces hydrogen bound though is less effective than 
trehalose (β: +1.94). It is reported that hydroxylalkyl cyclodextrins produce hydrogen bonds easier 
than their parent compound (19). In addition, we observed that incrementing the trehalose ratio has 
positive effect just in ratios from 0 to 0.6, and further increase did not provide more protection. This 
can be due to saturation of protein surface (Fig.9).  
Optimization was performed to find out the appropriate amount of each excipient and to obtain the 
best formulation. The optimal formulation was determined by using excipients in previously applied 
range to get the particle size range of 1.2 – 5.34 µm, with minimum particle size distribution and 
maximum value for other responses. The predicted optimal condition was composed of HPBCD, 
BCD, trehalose and antibody with ratios of 1: 0.99: 0.26: 1, respectively. Table 3 demonstrates the 
predicted values of all responses with this formulation. There was a reasonable agreement between 
the predicted and experimental values in all responses. 
Conclusion 
The type of excipients as well as their ratios in antibody formulation influenced yield, particle size, 
aerodynamic behavior and antibody stability. In particular, HPBCD not only enhanced aerosol 
performance of the powder, but also more effectively preserved the secondary structure and inhibited 
aggregation during spray drying. Also, trehalose is efficient in protection of antibody against 
aggregation in long term storage but did not influence particle aerodynamic behavior. Furthermore, 
BCD enhanced spray drying yield. The optimal formulation seems to be composed of HPBCD, 
BCD, trehalose and antibody with ratios of 1: 0.99: 0.26: 1, respectively.  
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Figure1. Effect of trehalose and BCD ratio on spray drying yield 
Figure2. the scanning electron microscopy of microparticles containing of BCD (a), HPBCD (b), trehalose(c) with the ratio of 1:1 to 
antibody and optimum formulation (d).  
Figure 3.Significant interactions HPBCD and trehaloseon particle size 
Figure 4. The close relationship between particle size and span 
Figure 5.The effect of HPBCD and Trehalose interaction on span 
Figure 6. Effect of various parameters on particle fine particle fraction (FPF) 
Figure 7. Effect of  augmentation of HPBCD and trehalose in antibody stability by measuring the Amount (%) of remained antibody 
monomer immediately after spray drying (A),1 monthstoring(B) and 3 month storing(C) 
Figure 8.FTIRsecondary derivative spectra of antibody of spray dried pure antibody and antibody with HPBCD, BCD and Trehalosein 
the ratio of 1:1. The peack position in 1940 cm -1 is the main band which indicatedthe antibody beta sheet content. 
Figure 9.The effect of trehalose and HPBCD ratios on preservation of antibody beta sheet content.  
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 Table 1. D-Optimal design and the responses from the analyses 
         Monomer  content 
Run Trehalose 
(A) 
HPBCD 
(B) 
BCD 
(C) 
Yield 
(%) 
Size 
(µm) 
Span  FPF 
(%) 
Βsheet 
(%) 
0 Days(30) Days(90) 
F 1 -1 -1 1 33.6 5.34 2.26 29.84 47.02 93 91.5 89.56 
F 2 0 0 1 35.33 5.07 2.24 19.27 59.04 96 97.33 95.29 
F 3 -1 1 1 32 3.16 1.29 41.62 55.7 99 96.73 95.13 
F 4 1 1 1 45.16 2.93 1.41 15.81 62.84 100 97.04 95.27 
F 5 -1 -1 -1 15.67 2.93 1.56 7.85 41.1 87.11 82.11 69.72 
F 6 0.5 -0.5 0 23.8 2.22 0.83 9.81 64.25 99.1 96.07 91.09 
F 7 0 1 0 27.17 1.9 1 35 63.47 97.2 96.77 92.53 
F 8 1 -1 1 33 2.1 0.82 22 60.16 98 97.12 92 
F 9 1 1 1 41.87 2.77 1.29 16 62.05 99.5 97.54 95.99 
F 10 -1 1 -1 27.2 2 1.72 52.23 57.74 98.2 96.56 92.56 
F 11 -1 1 -1 20 1.9 1.5 41.53 56.92 99.13 94.13 87.9 
F 12 1 0 -1 15.6 1.86 0.7 15.31 59.18 98 95.17 92.47 
F 13 -1 0 0 26.4 3.52 1.26 18.80 46.15 97.73 94.73 87.77 
F 14 1 1 -1 20.5 1.94 0.77 25 60.556 97 96.17 95.48 
F 15 1 -1 -1 18.6 1.2 0.55 17.44 66.32 95 92.43 90.29 
F 16 -1 -1 1 27.6 4.68 1.93 23 45.9 95.48 90.48 88.6 
F 17 0 -1 -1 19.6 2.66 1.15 23.73 66.74 96.39 94.39 87.32 
F 18 -1 1 1 28.33 2.79 1.21 45 56.74 99 99.9 96.2 
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 Table2. Fitted models and ANOVA analysis of various factors  
 Yield 
(%) 
Particle 
Size 
(µm) 
Span FPF 
(%) 
Monomer 
Content 
Day(0) 
Monomer 
Content 
Day(30) 
Monomer 
Content 
Day(90) 
β sheet 
content 
(%) 
Model < 0.0001 < 0.0001 0.006 0.0004 0.0035 0.0022 0.0003 < 0.0001 
A 0.1522 < 0.0001 0.0005 0.0019 0.036 0.0077 0.0008 < 0.0001 
B 0.0341 0.0466 0.770 0.0004 0.0048 0.0021 0.0005 0.0177 
C < 0.0001 < 0.0001 0.0596 0.7861 0.0829 0.012 0.0017 - 
A
2 - 0.0431 0.1060 0.1147 - - - 0.0003 
B
2 - 0.002 0.2234 0.009 - - - 0.0209 
C
2 - 0.004 0.0185 0.1907 - - - - 
AB 0.3171 0.0003 0.0287 0.0012 0.0273 0.0082 0.0271 0.0005 
AC 0.0138 - - 0.0711 - 0.3241 0.0095 - 
BC - - - 0.0108 - 0.3141 0.0686 - 
LoF 0.6935 0.2298 0.0580 0.5928 0.0531 0.1662 0.1333 0.0048 
A: Trehalose, B: Hydroxypropyl beta cyclodextrin, C: Beta cyclodextrin, LoF: Lack of fit 
 
 
 
 
Table 3. the value of optimized antibody formulation 
Response Yield 
(%) 
Particle Size 
(µm) 
Span FPF 
(%) 
βsheet 
content 
(%) 
Remained Monomer  
Day(0) Day(30)  Day(90)  
predicted 34.48 3.6 1.63 38.85 65.34 99.67 98. 3 96.0 
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